Man-Fung Yuen Selected Research

Hepatitis B e Antigens

11/2022	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
1/2022	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
1/2021	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
1/2020	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
1/2020	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.
1/2020	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.
12/2019	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
1/2019	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.
1/2019	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong.
1/2018	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Man-Fung Yuen Research Topics

Disease

135	Chronic Hepatitis B 11/2022 - 02/2002
57	Infections 11/2022 - 02/2002
57	Fibrosis (Cirrhosis) 11/2022 - 03/2002
57	Hepatocellular Carcinoma (Hepatoma) 05/2022 - 03/2002
54	Hepatitis B 01/2022 - 01/2003
16	Liver Cirrhosis (Hepatic Cirrhosis) 05/2022 - 12/2003
15	Neoplasms (Cancer) 04/2022 - 09/2002
11	Hepatitis 04/2022 - 02/2002
9	Liver Diseases (Liver Disease) 10/2022 - 08/2004
9	Disease Progression 01/2022 - 08/2004
8	Liver Neoplasms (Liver Cancer) 10/2022 - 12/2003
8	Chronic Hepatitis C 01/2022 - 02/2002
7	Viremia 01/2022 - 02/2002
6	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2014
4	Carcinogenesis 01/2021 - 05/2003
3	Fatty Liver 01/2022 - 01/2020
3	Chronic Hepatitis (Chronic Active Hepatitis) 01/2021 - 01/2006
3	Persistent Infection 01/2021 - 09/2008
3	Neoplasm Metastasis (Metastasis) 11/2020 - 09/2002
3	Alcoholic Liver Diseases (Alcoholic Liver Disease) 08/2020 - 01/2018
3	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2020 - 06/2017
3	Cholangitis 01/2020 - 07/2002
3	Sepsis (Septicemia) 07/2019 - 10/2014
3	Stomach Neoplasms (Stomach Cancer) 10/2012 - 05/2003
2	Diabetes Mellitus 01/2020 - 01/2019
2	Acute-On-Chronic Liver Failure 11/2019 - 07/2015
2	Substance-Related Disorders (Drug Abuse) 01/2018 - 09/2010
2	Coinfection 06/2017 - 01/2011
2	Inflammation (Inflammations) 01/2017 - 08/2013
2	Muscular Diseases (Myopathy) 03/2014 - 09/2010
2	Gastritis 08/2013 - 05/2003
1	Chronic Renal Insufficiency 02/2022

Drug/Important Bio-Agent (IBA)

61	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 07/2002
55	Hepatitis B Surface Antigens (HBsAg)FDA Link 05/2022 - 06/2004
54	Antiviral Agents (Antivirals)IBA 11/2022 - 03/2003
46	Hepatitis B e AntigensIBA 11/2022 - 11/2002
25	entecavir FDA Link 11/2022 - 01/2006
21	AntigensIBA 01/2022 - 06/2004
20	NucleosidesIBA 01/2022 - 12/2003
20	Lamivudine (Epivir)FDA Link 10/2017 - 07/2002
18	NucleotidesIBA 01/2022 - 11/2004
18	InterferonsIBA 12/2021 - 04/2003
16	Alanine Transaminase (SGPT)IBA 11/2022 - 11/2004
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2008
11	Proteins (Proteins, Gene)FDA Link 10/2022 - 10/2012
8	Tenofovir (Viread)FDA Link 02/2022 - 01/2011
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 03/2002
8	nasIBA 01/2022 - 01/2007
8	BilirubinIBA 12/2021 - 03/2002
8	Pharmaceutical PreparationsIBA 01/2021 - 01/2006
7	Ribavirin (Virazole)FDA LinkGeneric 01/2021 - 04/2003
7	Telbivudine FDA Link 12/2019 - 09/2004
6	RNA (Ribonucleic Acid)IBA 01/2022 - 02/2019
6	Circular DNAIBA 01/2022 - 10/2006
6	Immunoglobulins (Immunoglobulin)IBA 10/2017 - 10/2011
5	adefovirIBA 12/2019 - 01/2009
4	Messenger RNA (mRNA)IBA 01/2022 - 10/2006
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 09/2002
4	AlbuminsIBA 01/2020 - 08/2003
4	HLA-DP Antigens (HLA-DP)IBA 03/2014 - 01/2013
3	Reverse Transcriptase InhibitorsIBA 11/2022 - 09/2015
3	CateninsIBA 04/2022 - 05/2003
3	Transaminases (Aminotransferases)IBA 12/2021 - 01/2006
3	VaccinesIBA 12/2021 - 12/2008
3	Viral DNAIBA 01/2021 - 01/2017
3	BerberineIBA 08/2020 - 12/2015
3	((1- ((2- amino- 9H- purin- 9- yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxylIBA 01/2018 - 06/2014
3	hepatitis B hyperimmune globulinIBA 12/2015 - 06/2013
3	Cadherins (E-Cadherin)IBA 08/2013 - 05/2003
3	Interferon-alpha (Interferon Alfa)IBA 01/2013 - 06/2003
3	adefovir dipivoxil (Hepsera)FDA Link 01/2007 - 12/2003
2	Viral ProteinsIBA 10/2022 - 11/2019
2	ARC-520IBA 01/2022 - 01/2020
2	Amino Acids FDA Link 01/2021 - 09/2016
2	Carrier Proteins (Binding Protein)IBA 03/2019 - 07/2017
2	Surface Antigens (Surface Antigen)IBA 01/2018 - 01/2012
2	huanglianIBA 12/2015 - 01/2011
2	HLA Antigens (Human Leukocyte Antigens)IBA 03/2014 - 01/2014
2	Creatine Kinase (Creatine Phosphokinase)IBA 03/2014 - 09/2010
2	HLA-DPB1 antigen (HLA DPB1)IBA 01/2014 - 01/2013
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2013 - 10/2012
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 08/2013 - 10/2012
2	MicroRNAs (MicroRNA)IBA 08/2011 - 01/2011
1	IronIBA 06/2022
1	Protons (Proton)IBA 04/2022
1	Neutralizing AntibodiesIBA 04/2022
1	Polymeric Immunoglobulin Receptors (Polymeric Immunoglobulin Receptor)IBA 04/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	TransferasesIBA 01/2022
1	teleocalcinIBA 01/2022

Therapy/Procedure

73	Therapeutics 11/2022 - 02/2002
20	Liver Transplantation 01/2021 - 01/2003
5	Duration of Therapy 01/2021 - 08/2008
3	Renal Replacement Therapy (Therapies, Renal Replacement) 07/2019 - 02/2002
3	Aftercare (After-Treatment) 01/2018 - 01/2011
2	Withholding Treatment 01/2021 - 04/2015
2	Drug Therapy (Chemotherapy) 05/2016 - 11/2014
2	Stents 07/2014 - 10/2003
2	Blood Transfusion (Blood Transfusions) 03/2011 - 09/2010
2	Endoscopic Sphincterotomy 10/2003 - 07/2002